New combo therapy aims to stop bone cancer from coming back
NCT ID NCT05038124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a precise, high-dose radiation treatment (SBRT) to bone tumors before surgery is safe and can prevent the cancer from returning. About 39 adults with cancer that has spread to their bones and who need surgery to stabilize a fracture risk will receive SBRT followed by surgery within a week. The main goal is to check for serious wound complications and see if the cancer stays away from the treated bone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?
- Can a new nucleotide analogue boost cancer treatment?
- Zapping resistant tumors with precision radiation may extend the life of current cancer therapy
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?